Libtayo® (Cemiplimab-Rwlc) In Combination With Chemotherapy Approved By The FDA As First-Line Treatment For Advanced Non-Small Cell Lung Cancer (NSCLC)'

  • Israel Lowy,

Press/Media

Period8 Nov 2022 → 9 Nov 2022

Media coverage

109

Media coverage